{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02054455: Phase 4 Interventional Completed Gastrointestinal Symptoms
(2012)
Source URL:
First approved in 2020
Source:
BACICAP PROBIOTIC by NATIONAL BIO GREEN SCIENCES LIMITED LIABILTY COMPANY
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01927094: Phase 4 Interventional Completed Acute Diarrhea
(2012)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01686698: Phase 4 Interventional Completed Cirrhosis
(2013)
Source URL:
First approved in 2013
Source:
Fusion Plus by U.S. Pharmaceutical Corporation
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02462590: Phase 4 Interventional Completed Ventilator Associated Pneumonia
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT00849277: Phase 4 Interventional Completed Respiratory Tract Infections
(2006)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE